NASDAQ:AGTC - Applied Genetic Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.81
  • Forecasted Upside: 266.88 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$4.31
▲ +0.03 (0.70%)
1 month | 3 months | 12 months
Get New Applied Genetic Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGTC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.81
▲ +266.88% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Applied Genetic Technologies in the last 3 months. The average price target is $15.81, with a high forecast of $30.00 and a low forecast of $7.50. The average price target represents a 266.88% upside from the last price of $4.31.
Buy
The current consensus among 8 investment analysts is to buy stock in Applied Genetic Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Berenberg BankReiterated RatingBuy$11.00High
i
11/17/2020Roth CapitalBoost Price TargetBuy$25.00 ➝ $30.00Medium
i
11/11/2020Berenberg BankInitiated CoverageBuy$15.00High
i
9/9/2020Roth CapitalBoost Price TargetBuy$25.00 ➝ $26.00High
i
7/22/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/22/2020Chardan CapitalReiterated RatingBuy$7.50High
i
Rating by Gbola Amusa at Chardan Capital
6/22/2020Cantor FitzgeraldInitiated CoverageOverweight$14.00 ➝ $14.00High
i
Rating by K. Kluska at Cantor Fitzgerald
6/22/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/13/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/11/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by Joseph Pantginis at HC Wainwright
2/6/2020Chardan CapitalUpgradeBuy$10.00High
i
Rating by G. Amusa at Chardan Capital
1/27/2020Roth CapitalInitiated CoverageBuy$25.00High
i
Rating by Z. Jallah at Roth Capital
1/24/2020Janney Montgomery ScottReiterated RatingOutperform$18.00High
i
Rating by Yun Zhong at Janney Montgomery Scott
1/23/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/9/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/9/2020WedbushReiterated RatingBuy$12.00High
i
Rating by David Nierengarten at Wedbush
1/9/2020BMO Capital MarketsBoost Price TargetOutperform$9.00 ➝ $16.00High
i
Rating by Matthew Luchini at BMO Capital Markets
11/13/2019HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
9/27/2019WedbushBoost Price TargetOutperform$11.00 ➝ $12.00High
i
9/27/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$5.00 ➝ $9.00High
i
9/23/2019HC WainwrightReiterated RatingBuy$12.00 ➝ $18.00High
i
Rating by J. Pantginis at HC Wainwright
9/6/2019Janney Montgomery ScottInitiated CoverageBuy$13.00High
i
9/3/2019Chardan CapitalUpgradeNeutral ➝ Buy$7.50Low
i
Rating by G. Amusa at Chardan Capital
7/25/2019HC WainwrightReiterated RatingBuy$12.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/8/2019WedbushReiterated RatingOutperform$11.00Low
i
5/7/2019HC WainwrightBoost Price TargetBuy$5.75 ➝ $12.00Low
i
Rating by Joseph Pantginis at HC Wainwright
4/12/2019HC WainwrightSet Price TargetBuy$6.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
2/8/2019HC WainwrightReiterated RatingBuy$5.75High
i
Rating by Joseph Pantginis at HC Wainwright
12/13/2018Wells Fargo & CompanyLower Price TargetOutperform$20.00 ➝ $15.00High
i
12/13/2018HC WainwrightSet Price TargetPositive ➝ Buy$6.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/13/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00High
i
Rating by Matthew Luchini at BMO Capital Markets
11/8/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/24/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/24/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$20.00 ➝ $6.00High
i
9/11/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/11/2018Chardan CapitalDowngradeBuy ➝ Neutral$10.00 ➝ $5.00High
i
8/20/2018HC WainwrightSet Price TargetBuy$8.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
7/23/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/9/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Joseph Pantginis at HC Wainwright
2/9/2018WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
2/9/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Joseph Pantginis at HC Wainwright
1/17/2018Cantor FitzgeraldReiterated RatingHold$9.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
11/8/2017WedbushReiterated RatingOutperform$9.00N/A
i
11/8/2017HC WainwrightReiterated RatingBuy$8.00N/A
i
Rating by J. Pantginis at HC Wainwright
10/6/2017Cantor FitzgeraldSet Price TargetHold$9.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/14/2017HC WainwrightReiterated RatingBuy$16.00 ➝ $8.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/14/2017Cantor FitzgeraldLower Price TargetNeutral$15.00 ➝ $9.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/14/2017BMO Capital MarketsReiterated RatingOutperform$14.00 ➝ $7.00High
i
9/14/2017Stifel NicolausLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00High
i
8/10/2017HC WainwrightSet Price TargetBuy$16.00Low
i
Rating by Joseph Pantginis at HC Wainwright
6/10/2017HC WainwrightSet Price TargetBuy$16.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/11/2017Stifel NicolausLower Price TargetBuy ➝ Buy$18.00 ➝ $15.00High
i
5/10/2017Cantor FitzgeraldSet Price TargetHold$15.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/15/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$16.00High
i
2/9/2017Stifel NicolausLower Price TargetBuy$22.00 ➝ $18.00N/A
i
2/9/2017WedbushReiterated RatingOutperform$15.00N/A
i
2/9/2017BMO Capital MarketsLower Price TargetBuy$20.00 ➝ $14.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
2/8/2017Cantor FitzgeraldSet Price TargetHold$15.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/13/2016BMO Capital MarketsReiterated RatingOutperform$20.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
11/9/2016BMO Capital MarketsReiterated RatingBuy$20.00N/A
i
Rating by matthew luchini at BMO Capital Markets
11/9/2016Roth CapitalUpgradeNeutral ➝ Buy$12.00 ➝ $15.00N/A
i
Rating by J. Pantginis at Roth Capital
11/9/2016WedbushReiterated RatingOutperform$20.00 ➝ $17.00N/A
i
10/23/2016Roth CapitalReiterated RatingNeutral$12.00N/A
i
9/26/2016Janney Montgomery ScottUpgradeSell ➝ Neutral$11.00N/A
i
Rating by debjit chattopadhyay at Janney Montgomery Scott
9/13/2016Roth CapitalDowngradeBuy ➝ Neutral$34.00 ➝ $12.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/13/2016BMO Capital MarketsLower Price TargetOutperform$25.00 ➝ $20.00N/A
i
9/13/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$32.00 ➝ $15.00N/A
i
Rating by M. Goldstein at Cantor Fitzgerald
9/13/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
9/13/2016Janney Montgomery ScottDowngradeBuy ➝ Sell$23.00 ➝ $11.00N/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
9/13/2016Stifel NicolausLower Price TargetBuy$29.00 ➝ $24.00N/A
i
9/13/2016WedbushLower Price TargetOutperform$36.00 ➝ $20.00N/A
i
6/22/2016Cantor FitzgeraldReiterated RatingBuy$32.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
5/10/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
5/10/2016Cantor FitzgeraldReiterated RatingBuy$32.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
5/10/2016WedbushReiterated RatingOutperform$36.00N/A
i
4/25/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Joseph Pantginis at Roth Capital
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$25.00N/A
i
3/18/2016Janney Montgomery ScottInitiated CoverageBuy$23.00N/A
i
2/9/2016Stifel NicolausLower Price TargetBuy$32.00 ➝ $29.00N/A
i
2/9/2016Cantor FitzgeraldReiterated RatingBuy$32.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
1/10/2016Chardan CapitalReiterated RatingBuy$25.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
12/17/2015Cantor FitzgeraldReiterated RatingBuy$32.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/11/2015Cantor FitzgeraldReiterated RatingBuy$32.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
(Data available from 11/24/2015 forward)
Applied Genetic Technologies logo
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $4.31
$4.18
$4.37

50 Day Range

MA: $5.19
$3.99
$5.70

52 Week Range

Now: $4.31
$2.29
$10.42

Volume

9,206 shs

Average Volume

600,632 shs

Market Capitalization

$111.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.62